Home
overview
The global market for anti-infective drugs continues to expand as pathogens rapidly mutate and become resistant to current treatments at an alarming rate. The market size for anti-microbial agents now exceeds $52 billion per year. As technological advancements and the understanding of microbial genetics accelerate, the potential for new therapies is undoubtedly there but the question is how can this potential be harnessed to develop a marketable drug?

The majority of drugs coming onto the market in the next couple of years are modified forms of existing classes. The real challenge to industry is developing innovative new classes of drugs that will tackle resistance in bacteria. This Conference will evaluate the current developments, both in terms of advances in drug discovery and in terms of the relative success of projects in the pipeline.

A UNIQUE OPPORTUNITY TO HEAR FROM LEADING EXPERTS INCLUDING:
· Dr Janice Soreth, Director, Anti-Infective Drug Products, US Food & Drug Administration (FDA)
· Dr John Barrett, Senior Director, Antibacterial Drug Discovery, Merck
· Dr Michael Barbachyn, Director, Antibacterial Chemistry, Pfizer
· Dr Kathryn Braken, Associate Director, Infectious Disease, Novartis
· Dr Patricia Bradford, Associate Director, Infectious Disease Discovery Research, Wyeth
· Prof Paul Manning, Head, Molecular Sciences, Infection Discovery, AstraZeneca
· Dr Angela Nilius, Manager, Scientific Operations, Clarithromycin Global Project Team, Abbott
· Dr Yat Sun Or, Senior Vice President, Research & Development, Enanta Pharmaceuticals
· Dr Barry Eisenstein, Executive Vice President, Research & Development, Cubist
· Dr Nafsika Georgopapadakou, Vice President, Infectious Disease, MethylGene

BENEFITS OF ATTENDING:
· OUTPACING THE MICROBES: How does industry plan to overcome the problem of bacterial resistance?
· ANTIBIOTICS: Old or new? Learn where the progress is being made
· MECHANISMS OF ACTION: Examine the pathways novel drugs are targeting, and how they work
· OVERCOMING RESISTANCE BY DESIGN: Can structure-based drug design deliver?
· FUTURE DRUGS: Identify the promising new classes of drugs that are providing increased hope in the battle against bacteria
· NETWORK WITH KEY EXPERTS: Discuss and exchange ideas with leaders in the field

“Great Conference, great settings! Terrific scientific Conference for ‘taking the pulse’ of R & D in antibiotic research.”
Dr John Barrett, Senior Director, Antibacterial Drug Discovery, Merck
Speaker, SMi’s Superbugs & Superdrugs Conference 2003

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Bruce Rogers

Dr Bruce Rogers, Senior Director, Preclinical Development, Genome Therapeutics

9:10 INDUSTRY OVERVIEW

Laura Harris

Laura Harris, Antibacterials Analyst, Datamonitor

  • What drugs have surfaced over the past year?
  • What’s in the development pipeline?
  • Emergence of the novel drug classes
  • Where is the field headed?
  • 9:40 INDUSTRY CHALLENGES

    Dr John Barrett

    Dr John Barrett, Senior Director, Antibacterial Drug Discovery, Merck

  • How can industry keep up with bacterial evolution?
  • What discovery and development strategies can be employed?
  • Anti-infectives in the post-genomic era
  • What are the current issues in hit to lead?
  • An overview of the drug classes which are showing most promise
  • 10:20 FDA – GUIDANCE TO INDUSTRY

    Dr Janice Soreth

    Dr Janice Soreth, Director, Anti-Infective Drug Products, CDER, US Food & Drug Administration (FDA)

  • Stimulating drug development in anti-infectives
  • Antibiotic resistance and incentives for development
  • Delta selection in anti-infective trials
  • 11:00 Morning Coffee

    11:20 CHALLENGES OF THE ‘GENE TO DRUG’ PARADIGM FOR ANTIBACTERIALS

    Prof Paul Manning

    Prof Paul Manning, Head, Molecular Sciences, Infection Discovery, AstraZeneca

  • How can we select from the large number of potential targets?
  • Selection of bacterial species for validation of target
  • Isozyme/target selection for screening
  • Whole cell activity and efflux
  • Expression profiling to confirm mode of action
  • Where are we at with this approach?
  • 12:00 FUNCTIONAL GENOMICS IN ANTIBACTERIAL DRUG DISCOVERY

    Dr Heike Brötz-Oesterhelt

    Dr Heike Brötz-Oesterhelt, Senior Scientist, Antibacterial Research, Bayer HealthCare

  • Innovative techniques for mode of action studies
  • Proteomics – investigating the effector molecules of the cell
  • RNA expression profiling – monitoring all genes in parallel
  • FTIR-spectroscopy – what can we learn without even breaking the cell?
  • Target identification (validation) of novel lead compounds
  • 12:40 Networking Lunch

    13:40 ANTIBIOTIC MECHANISM OF ACTION (MOA) AND RESISTANCE

    Dr Joyce Sutcliffe

    Dr Joyce Sutcliffe, Vice President, Biochemistry & Molecular Biology, Rib-X Pharmaceuticals

  • How does knowing the MOA impact drug design?
  • Can structure-based drug design be used to overcome resistance?
  • Can structure-based drug design deliver?
  • 14:20 OXAZOLIDINONES

    Dr Michael Barbachyn

    Dr Michael Barbachyn, Director, Antibacterial Chemistry, Pfizer

  • Medical need for new antibacterial agents
  • Emergence of ZyvoxTM
  • Antibacterial spectrum and potency
  • Effectiveness against multi-drug resistant bacteria
  • Mechanism of action
  • Emergence and mechanism of resistance
    Long-term potential of this class
  • 15:00 PEPTIDE DEFORMYLASE INHIBITORS

    Dr Kathryn Braken

    Dr Kathryn Braken, Associate Director, Infectious Disease, Novartis

  • Peptide deformylase inhibitors as potent and selective novel antibacterial agents
  • Mechanism-based rational design - challenges and progress
  • Future prospects for this class of antibacterial agent
  • 15:40 Afternoon Tea

    16:00 KETOLIDES

    Dr Yat Sun Or

    Dr Yat Sun Or, Senior Vice President, Research & Development, Enanta Pharmaceuticals

  • Are there real contenders in this class?
  • What are they?
  • Evaluation of Abbotts ABT773 and Aventis’ Ketek
  • Other candidates
  • Future prospects
  • 16:40 ß -LACTAMASE INHIBITORS

    Dr Nafsika Georgopapadakou

    Dr Nafsika Georgopapadakou, Vice President, Infectious Disease, MethylGene

  • The ABCs of ß-lactamases
  • Drawbacks of current ß-lactam/inhibitor combinations
  • New inhibitors: penems, cephems, monobactams, boronates, phosphonates
  • The quest for a universal inhibitor - phosphonates
  • The importance of target access in Gram-negative bacteria
  • Prospects for ß-lactam and non-ß-lactam inhibitors
  • 17:02 NOVEL ANTI-INFECTIVE AGENTS TO PREVENT BIOFILM FORMATION

    Dr Richard Bott

    Dr Richard Bott, Scientist, Protein Biophysical Sciences, Genencor

  • Bacterial adhesins
  • Targeting strategy
  • Enzymatic degradation of adhesins
  • 18:00 Chairman’s Closing Remarks and Close of Day One

    8:03 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    William Weiss

    William Weiss, Group Leader, Antimicrobial Chemotherapy, Wyeth

    9:10 RELEVANCE OF EFFLUX IN BACTERIAL RESISTANCE

    Dr Angela Nilius

    Dr Angela Nilius, Manager, Scientific Operations, Clarithromycin Global Project Team, Abbott

  • Importance of population density
  • Role of efflux in bacteria
  • Is it a druggable pathway?
  • Why should industry invest in this area?
  • 9:40 LIPOPETIDES

    Dr Barry Eisenstein

    Dr Barry Eisenstein, Executive Vice President, Research & Development, Cubist

  • Medical need in Gram-positive infections (increasing drug resistance and the inadequacies of vancomycin)
  • Potency and mechanism of action
  • Spectrum of activity
  • Potential for treating Gram-positive bacteria
  • Update and placement in the clinic
  • 10:20 GYRASE B DIRECTED DRUGS

    Dr Jeffrey Stein

    Dr Jeffrey Stein, Chief Scientific Officer, Quorex Pharmaceuticals

  • A clinically validated yet ‘novel’ target
  • Attractive replacements for the threatened quinolone market?
  • Rapid structure-guided optimisation and parallel chemistry yield potent inhibitors
  • Efficacy and safety profiles point to broad market penetration
  • 11:00 Morning Coffee

    11:20 NOVEL DUAL TARGETING AGENTS

    Dr Paul Charifson

    Dr Paul Charifson, Project Leader, Gryase B Programme, Vertex

  • Gyrase and topoisomerase IV as validated targets
  • The design of potent dual inhibitors using structure-based design
  • In vivo evaluation
  • 12:00 RAMOPLANIN: A NOVEL ANTIBIOTIC WITH A NEW MECHANISM OF ACTION

    Dr Bruce Rogers

    Dr Bruce Rogers, Senior Director, Preclinical Development, Genome Therapeutics

  • Potent activity against resistant organisms
  • New mechanism of action for peptidoglycan biosynthesis inhibition
  • Effective killing of pathogen biofilms
  • Clinical progress and future prospects
  • 12:40 Networking Lunch

    13:40 NOVEL APPROACHES IN ANTI-INFECTION THERAPEUTICS

    Dr Michael Alekshun

    Dr Michael Alekshun, Associate Director, Anti-Infective Drug Discovery, Paratek

  • Current problems of multiple antibiotic resistant bacteria
  • Current therapeutic options
  • Functions of Mar proteins in microbial virulence
  • SBDD of novel Mar inhibitors
  • Are transcription factors druggable?
  • 14:20 ANTI-MRSA CEPHALOSPORINS

    Prof Malcolm Page

    Prof Malcolm Page, Head, Biology, Basilea Phamaceutica

  • Clinical resistance to b-lactams mediated by PBPs
  • Current understanding of the molecular basis of PBP-mediated resistance in Gram-positive cocci
  • Contrasting situation of resistance in Gram-negative bacteria (Neisseria, Haemophilus and Pseudomonas)
  • Addressing MRSA infection with b-lactams
  • Mechanism of action of a model compound
  • The anti-MRSA cephalosporins currently in development
  • 15:00 ADAPTABILITY OF GRAM-NEGATIVE BACTERIA

    Dr Patricia Bradford

    Dr Patricia Bradford, Associate Director, Infectious Disease Discovery Research, Wyeth

  • Efflux pumps come and go
  • Outer membrane proteins work in concert with other resistance mechanisms
  • Evolution of ß-lactamases: experience in a NYC hospital
  • Prospects for future therapies
  • 15:40 Afternoon Tea

    16:00 CARBAPENEMASES: TIP OF THE ICEBERG?

    Dr Timothy Walsh

    Dr Timothy Walsh, Senior Lecturer, Clinical Microbiology, Bristol University

  • Review methods for detecting them and examine their worldwide distribution
  • Examine how metallo-ß-lactamase genes spread and the problem of co-resistance
  • Can we inhibit metallo-ß-lactamases using the co-amoxiclav paradigm?
  • 16:40 INNOVATIVE AMBULATORY TECHNOLOGIES FOR DIAGNOSIS AND MONITORING INFECTIOUS DISEASE

    To be Confirmed

    To be Confirmed, , Mini Mitter

  • Non-invasive ambulatory ingestible core body temperature and comfortable heart rate sensors
  • Integration of core body temperature and heart rate to enhance diagnostic prediction
  • Accurate, non-invasive, animal monitors to evaluate the development of sepsis
  • 17:20 Chairman's Closing Remarks and Close of Conference

    +

    Workshops

    PK-PD in Antimicrobial Drug Development
    Workshop

    PK-PD in Antimicrobial Drug Development

    The Hatton, at etc. venues
    3rd March 2004
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.